Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject completed study M02-518 or M02-570~Exclusion Criteria:~* Subject prematurely discontinued study M02-518 or M02-570~  * Female subject who is pregnant or breast-feeding or considering becoming pregnant~ * Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).